Author

Udhayvir S. Grewal

Observed name: Udhayvir S Grewal

Institutions: University of Iowa, Emory University, University of Iowa Hospitals and Clinics, University of Iowa Health Care, Winship Cancer Institute, University of Iowa Holden Comprehensive Cancer Center

Observed institutions: University of Iowa, Emory University, University of Iowa Hospitals and Clinics, University of Iowa Health Care, Winship Cancer Institute, University of Iowa Holden Comprehensive Cancer Center

ORCID: 0000-0002-9638-3629

Observed ORCID: 0000-0002-9638-3629

OpenAlex ID: A5134699590

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies

2026 · Udhayvir S. Grewal, Shagufta Shaheen, et al. · American Society of Clinical Oncology Educational Book · 2

Optimizing Systemic Therapy in Advanced Gastrointestinal Malignancies: Strategies to Minimize Toxicity and Maximize Tolerability

2026 · Sabrina Bulancea, Udhayvir S. Grewal, et al. · Clinical Colorectal Cancer · 1

Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data

2026 · Michael A. O’Rorke, Bradley D. McDowell, et al. · Endocrine · 1

Clinical Significance of Interim Anatomic Imaging in Patients with Neuroendocrine Tumors Receiving 177Lu-DOTATATE

2026 · Udhayvir S. Grewal, Rishi R. Patel, et al. · World Journal of Nuclear Medicine

Comparative Analysis of Characteristics and Outcomes of Patients with Early-Onset Versus Average-Onset Small Bowel Neuroendocrine Tumors

2026 · Matthew T. Gao, Rishi R. Patel, et al. · American Journal of Clinical Oncology

Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues

2026 · Charles W. Shi, Aagamjit Singh, et al. · European Journal of Cancer

Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement

2026 · Udhayvir S. Grewal, Po H. Ear, et al. · Cancer

Patient‐reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes

2026 · Timothy J. Brown, Nicholas J. Hornstein, et al. · Cancer

Care Patterns and Gastric Cancer-Related Outcomes in Patients With Pathogenic/Likely Pathogenic Germline CDH1 Variants

2026 · Robert Schoeneich, Rishi R. Patel, et al. · American Journal of Clinical Oncology

Outcomes With Peptide Receptor Radionuclide Therapy in Patients With Pheochromocytoma/Paraganglioma: A Center of Excellence Experience

2026 · Matthew T. Gao, Rishi R. Patel, et al. · American Journal of Therapeutics

Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy

2026 · Emilie AK Warren, Madeline D Roorbach, et al. · Endocrine Related Cancer

Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey

2026 · Udhayvir S. Grewal, Rishi R. Patel, et al. · Cancer

Works count: 12

Citation count: 4

H-index: 1

I10-index: